Since experimentally validated AMPs were used, the assumption is that the profiles developed ought to have the option to recognize different sequences with precisely the same action and separate those that have no anti-pneumonia activity from the same microorganism. The gene discussed is ADSL; the disease is susceptibility to pneumonia measurement.